MétaCan
Menu
Back to cohort

S64 Clinical Efficacy and Safety of Treatments for Exocrine Pancreatic Insufficiency: A Systematic Literature Review

2023· article· en· W4387733076 on OpenAlexaff
Paula Chu, Jasmina Mioc, Owen S. Henry, Peter O’Donovan, Louise Heron

Bibliographic record

VenueThe American Journal of Gastroenterology · 2023
Typearticle
Languageen
FieldMedicine
TopicChild Nutrition and Feeding Issues
Canadian institutionsMerck Canada Inc. (Canada)
Fundersnot available
KeywordsMedicinePlaceboObservational studyPancreatitisInternal medicineExocrine pancreatic insufficiencyRandomized controlled trialMeta-analysisSystematic reviewClinical trialCystic fibrosisMEDLINEGastroenterologyAlternative medicinePathology

Abstract

fetched live from OpenAlex

Introduction: Exocrine pancreatic insufficiency (EPI) is caused by multiple clinical conditions such as cystic fibrosis (CF) and chronic pancreatitis. Standard management of EPI includes Pancreatic Enzyme Replacement Therapy (PERT) along with consultation with a dietitian. While PERT has been on the market for several decades, newer publications on the clinical efficacy and safety of PERT necessitated a comprehensive update of the literature. We aimed to identify the available evidence on the clinical efficacy and safety of treatments for EPI to understand the current treatment landscape. Methods: A systematic literature review was conducted in Embase, Medline, and Evidence-Based Medicine databases from 2010–2022; conference proceedings from 2020–2022 were also searched. Articles were screened independently by 2 reviewers at abstract and full text stage against pre-defined eligibility criteria. Results: We identified 26 journal publications and 2 conference abstracts, reporting on 22 randomized control trials, 4 observational studies and 2 single arm interventional studies. The most reported investigational treatment was pancrelipase, specifically Creo (n=12). Thirteen studies reported coefficient of fat absorption (CFA) results. Across studies, patients experienced an increase in CFA post initiation of treatment regardless of intervention or timepoint. Mean change in CFA ranged from 7.5% in patients with CP who received placebo to 36% in patients with CP treated with Creon®. Nine studies reported coefficient of nitrogen absorption (CNA). Mean change in CNA ranged from 3.7% in patients with CP receiving placebo to 39.1% in patients with CP treated with Creon®. When compared to placebo, pancrelipase increased CNA levels. Only one study compared PERT brands head-to-head; however, no significant differences were reported in the CNA-72 h values (Creon® 82.0% [SE1.2] vs Zenpep® 80.9% [SE 1.2]). Twelve studies reported body weight and body mass index (BMI); overall, treatment with PERT increased BMI and body weight or limited their decline. Creon increased BMI and body weight, with increases ranging from 0.1 to 6.1kg. Eighteen studies reported safety outcomes; overall, PERT was considered safe and well tolerated. Conclusion: This review confirmed that PERT is an effective and tolerable treatment option in patients with EPI. In the available evidence there was limited evidence for nutritional parameters and health-related quality of life.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.050
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.012
Threshold uncertainty score0.056

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0110.050
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0100.009
Bibliometrics0.0120.013
Science and technology studies0.0010.001
Scholarly communication0.0030.003
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0100.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.355
Teacher spread0.328 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicChild Nutrition and Feeding IssuesFrench-language works237,207